Gradientech announces outcome of rights issue

Uppsala, 3 January, 2022. Gradientech AB (publ) (“Gradientech” or “the Company”) announces that the Company's rights issue (the “Rights Issue”), in which the subscription period ended on December 23, 2021, has been completed. The final count in the Rights Issue shows that 3,675,316 shares, corresponding to 90 percent of the Rights Issue, were subscribed for with and without the support of subscription rights. Through the Rights Issue, Gradientech will receive approximately SEK 75.3 million before deductions for transaction costs.

Outcome
The rights issue comprised a maximum of 4,068,607 shares, of which 2,041,792 shares, corresponding to approximately 50 percent of the Rights Issue, have been subscribed for with the support of subscription rights. 416,264 shares, corresponding to approximately 10 percent of the Rights Issue, have been registered for subscription without the support of subscription rights. In addition, 1,217,260 shares, corresponding to 30 percent, were subscribed for through the fulfillment of investment commitments. A total of 3,675,316 shares, corresponding to approximately 90 percent of the Rights Issue, have been subscribed for with and without the support of subscription rights.

Notification regarding allocation

Allotment of shares has taken place in accordance with the allotment principles described in the prospectus published in connection with the Rights Issue. A notification regarding allocation of shares subscribed for without the support of subscription rights will be made by a settlement note sent to each subscriber. Allotted shares subscribed for without the support of subscription rights shall be paid in accordance with the instructions on the settlement note.

BTA

BTA (Sw. betald tecknad aktie) will be converted into ordinary shares when the Rights Issue is registered with the Swedish Companies Registration Office, which is expected to take place around week 2, 2022.

Number of shares and share capital

The rights issue provides Gradientech with proceeds amounting to approximately SEK 75.3 million before transaction costs. As a result of the Rights Issue, the Company's share capital will increase by SEK 367,531.60 to a total of SEK 1,588,113.90 and the total number of shares will increase by 3,675,316 shares to 15,881,139 shares.

Advisor

Redeye is the financial advisor and Lindahl KB acts as the legal advisor to Gradientech in connection with the Rights Issue. Nordic Issuing acts as an issuing agent.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala. Visit www.gradientech.se for more information.